Tutluoglu Bülent, Gurel Cigdem Bayram, Ozdas Sule Beyhan, Musellim Benan, Erturan Serdar, Anakkaya A Nihat, Kilinc Günseli, Ulutin Turgut
Istanbul University Cerrahpasa Faculty of Medicine, Istanbul.
Clin Appl Thromb Hemost. 2005 Jan;11(1):77-81. doi: 10.1177/107602960501100109.
Platelets have the capacity to release mediators with potent inflammatory or anaphylactic properties. Platelet factor-4 (PF4) and beta-thromboglobulin (BTG) are two of these mediators. On the other hand, plasminogen activator inhibitor-1 (PAI-1) and tissue plasminogen activator (tPA) are two important mediators of fibrinolysis. Both mediators are secreted mainly by vascular endothelium. Plasma levels of PF4, BTG, PAI-1, and tPA may show changes in chronic inflammatory diseases such as asthma. This study examined the role of thrombocytes and the function of the endothelium in asthmatic patients during an attack and during a stable phase. Eighteen patients with known allergic asthma who came to our emergency department with an asthma attack and 14 control subjects were included in the study. Blood samples were taken after starting therapy with salbutamol inhalation. Lung function tests were performed after receiving the first emergency therapy for asthma. Plasma levels of PF4, BTG, PAI-1, tPA were determined before starting steroid therapy and after receiving 1 week of steroid therapy. Plasma levels of PF4 among patients with an asthma attack were significantly higher than those of controls (150.5+/-8.92 IU/mL vs. 92.5+/-7.63 IU/mL, p<0.001). A further increase in plasma PF4 levels was detected after steroid therapy (163.5+/-9.16 IU/mL). Plasma BTG levels of patients on admission were not statistically different from those in the control group (140.4+/-6.34 IU/mL vs. 152.2+/-8.71 IU/mL). An increase was detected after therapy (171.6+/-7.27 IU/mL) and post-treatment plasma levels were statistically meaningful versus the controls. Plasma levels of tPA and PAI were statistically higher than those in controls in asthmatic patients on admission (6.01+/-2.72 vs. 5.4+/-2.3 ng/mL for tPA and 75.2+/-27.2 ng/mL vs. 32.7+/-14.3 ng/mL for PAI-1). Further increases were detected in two parameters after 1 week of therapy with steroids (tPA levels were 6.85+/-2.96 ng/mL and PAI-1 levels were 83.5+/-29.6 ng/mL). There seems to be an increased activity of platelets during an asthma attack. Elevated PAI-1 and tPA levels may also indicate the activated endothelium in asthma. Increases of plasma levels of PAI-1 and tPA after steroid therapy need further investigation because elevated PAI-1 levels enhance airway remodeling.
血小板具有释放具有强大炎症或过敏特性介质的能力。血小板因子-4(PF4)和β-血小板球蛋白(BTG)就是其中两种介质。另一方面,纤溶酶原激活物抑制剂-1(PAI-1)和组织纤溶酶原激活物(tPA)是纤维蛋白溶解的两种重要介质。这两种介质主要由血管内皮分泌。PF4、BTG、PAI-1和tPA的血浆水平在哮喘等慢性炎症性疾病中可能会发生变化。本研究探讨了哮喘患者发作期和稳定期血小板及内皮功能的作用。本研究纳入了18例因哮喘发作前来我院急诊科的已知过敏性哮喘患者和14例对照者。在开始吸入沙丁胺醇治疗后采集血样。在接受首次哮喘急救治疗后进行肺功能测试。在开始使用类固醇治疗前及接受1周类固醇治疗后测定PF4、BTG、PAI-1、tPA的血浆水平。哮喘发作患者的PF4血浆水平显著高于对照组(150.5±8.92 IU/mL对92.5±7.63 IU/mL,p<0.001)。类固醇治疗后检测到PF4血浆水平进一步升高(163.5±9.16 IU/mL)。入院时患者的BTG血浆水平与对照组无统计学差异(140.4±6.34 IU/mL对152.2±8.71 IU/mL)。治疗后检测到升高(171.6±7.27 IU/mL),且治疗后血浆水平与对照组相比具有统计学意义。哮喘患者入院时tPA和PAI的血浆水平在统计学上高于对照组(tPA为6.01±2.72对5.4±2.3 ng/mL,PAI-1为75.2±27.2对32.7±14.3 ng/mL)。类固醇治疗1周后,这两个参数进一步升高(tPA水平为6.85±2.96 ng/mL,PAI-1水平为83.5±29.6 ng/mL)。哮喘发作期间似乎血小板活性增加。PAI-1和tPA水平升高也可能表明哮喘患者内皮激活。类固醇治疗后PAI-1和tPA血浆水平升高需要进一步研究,因为PAI-1水平升高会加剧气道重塑。